Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the clinical efficacy, biologic activity
(inhibition of PX-12 target thioredoxin-1) and effects of an expired metabolite of PX-12 in
patients with advanced pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Cascadian Therapeutics Inc.
Collaborators:
National Cancer Institute (NCI) Translational Genomics Research Institute